Rutatsid tab Gesves. 500mg 20 pieces


Rutatsid tab Gesves. 500mg 20 pieces

5 in stock



Active substance:
1 tablet contains:
Hydrotalcite 500.00 mg.
Mannitol, saccharin sodium, sodium carboxymethyl starch, talc, magnesium stearate, flavor, peppermint.
Round tablets white or nearly white with a chamfer with a light minty smell.
Product form:
Chewable Tablets, 500 mg.
10 tablets in the blister of the composite material of PVC / PVDC and aluminum foil.
2 or 6 blisters together with instructions for use placed into cardboard pack.
Hypersensitivity to the active agent or other components included in the preparation.
Severe renal insufficiency.
Myasthenia gravis.
Children up to age 6 years.
500 mg
Acute and chronic gastritis.
Gastric ulcer and duodenal ulcer.
Reflux esophagitis.
Heartburn and other symptoms of gastro-intestinal tract caused by high acidity of gastric juice.
Interaction with other drugs
Should not be taken simultaneously with the drugs, the absorption of which may affect the use of hydrotalcite (m. E. Glycosides, tetracycline or quinolone derivatives, such as ofloxacin and ciprofloxacin, antagonists of histamine H2-receptors, derivatives of coumarin, sodium fluoride, chenodeoxycholate).
Typically, all other drugs should be taken at least 1-2 hours before or after taking the drug Rutatsid®.
Currently, the cases of drug overdose Rutatsid® were reported.
pharmachologic effect
Pharmacological group:
Pharmacological properties:
Hydrotalcite is an antacid preparation. Has a crystalline layered mesh structure with a low content of aluminum and magnesium. 1 g of hydrotalcite has minimal buffering capacity of 26 meq. The drug provides rapid and prolonged neutralization of gastric hydrochloric acid with maintaining pH at an optimum therapeutic level between 3 and 5 exerts gidroprotektivnoe action due to prolonged binding of pepsin, hydrochloric acid, bile acids, also activates its own gastric defense factors.
Due layered mesh structure Rutatsid® drug release aluminum and magnesium ions in the stomach occurs gradually as a function of pH. When used in therapeutic doses preparation Rutatsid® practically not absorbed from the gastrointestinal tract. In this case magnesium and aluminum content in the blood plasma remains within the physiological limits.
Pregnancy and breast-feeding
As with other drugs during pregnancy and breastfeeding Rutatsid® drug should be taken only after consulting a doctor. Despite the fact that the pharmacokinetic studies have shown that after taking hydrotalcite aluminum content in the blood plasma remains within the physiological norm, Rutatsid® drug should be used during pregnancy only for a short period of time, to minimize the possible effects of aluminum on the unborn child.
Typically, the aluminum-containing substances are secreted in breast milk. Data supporting the removal of the breast milk when applied Rutatsid® drug, no. However, absorption in the intestine of the mother and the child is low, so there is no risk to the health of newborns.
Conditions of supply of pharmacies
Without a prescription.
side effects
Disorders of the gastrointestinal tract: when using the drug in high doses may loose stools, increased stool frequency, vomiting, diarrhea.
Laboratory and instrumental data: reduction of phosphorus in the blood, plasma gipermagniemiya.
Disorders of immune system: allergic reactions.
Long-term treatment of patients with renal failure may lead to intoxication with aluminum encephalopathy and osteomalacia.
special instructions
Patients with impaired renal function (especially in patients on hemodialysis) patients with Alzheimer’s disease or other forms of dementia or patients with hypophosphatemia or a diet with reduced phosphate content, the drug should not be taken in high doses Rutatsid®, prolonged use of the drug as Not recommended.
Hydrotalcite should not be taken with food containing acid (wine, fruit juice, etc.), Due to increased absorption of aluminum hydroxide in the intestine.
Rutatsid® drug does not contain sucrose, so it may take patients with diabetes mellitus.
Polyols (mannitol) may cause diarrhea.
Effects on ability to perform potentially hazardous activities that require attention and fast reactions (eg, road management, work with moving machinery) is not affected.
Storage conditions
At temperatures above 25 C, in the original package.
Keep out of the reach of children.
Dosing and Administration
Ingest. Tablets should be chewed and, if desired, drink water.
Adults and children over 12 years:
Acute and chronic gastritis, reflux esophagitis: 500-1000 mg of (1-2 tablets) 1-2 hours after meals and at bedtime, and also if necessary.
Peptic ulcer and duodenum 12: 1,000 mg (2 tablets) 3-4 times a day after meals and at bedtime. Treatment should be continued for 4 weeks after the complete disappearance of symptoms.
Heartburn and other symptoms from the gastrointestinal tract associated with the acidity of gastric contents: 500-1000 mg of (1-2 tablets) if necessary.
Hydrotalcite maximum daily dose should not exceed 6000 mg (12 tablets).
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg

Krka UTS

There are no reviews yet.

Add your review